EP Patent

EP0829478A3 — N-Benzylimidazolium and N-benzyltriazolium derivatives, their preparation and their use as antifungal and antimycotic agents

Assigned to F Hoffmann La Roche AG · Expires 1998-03-25 · 28y expired

What this patent protects

N-Benzylazolium derivatives of the general formula (I), wherein    Q is the remainder of an azole compound of the formula II possessing antifungal activity; Z is nitrogen or methine; R 1 and R 2 are each independently a hydrogen atom or a group -OY [in which Y …

USPTO Abstract

N-Benzylazolium derivatives of the general formula (I), wherein    Q is the remainder of an azole compound of the formula II possessing antifungal activity; Z is nitrogen or methine; R 1 and R 2 are each independently a hydrogen atom or a group -OY [in which Y is a group easily hydrolyzable under physiological condition]; R 3 and R 4 are each independently a hydrogen or halogen atom, lower alkyl, lower alkoxy, lower alkylthio, (lower alkylcarbonyl)thiomethyl, carboxy or methoxycarbonyl; and X - is a pharmaceutically acceptable anion, as well as salts, hydrates or solvates of the compounds of the general formula (I) have antifungal properties.

Drugs covered by this patent

Patent Metadata

Patent number
EP0829478A3
Jurisdiction
EP
Classification
Expires
1998-03-25
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.